Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Recent updates on GLP-1 agonists: current advancements & challenges
DOI: 10.1001/jama.2025.14392 Lyons SA, Beaudry JL
Rise in Off-Label GLP-1 Prescribing Highlights Need for Equitable Access Brian Nowosielski In association with patients race, ethnicity, and social determinants of health, researchers explored the off-label prescribing of GLP-1s approved for type 2 diabetes
Conclusion: Choosing the Great Life Ultimately, the rise of GLP-1 drugs serves as a mirror, reflecting our society's desire for quick solutions to complex, systemic problems
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
